Corresponding cumulative incidences for endometrial cancer were 38.2% (95% CI (29.0–47.4)) versus 34.9% (95% CI (19.2–50.6)) for path_MLH1 carriers and 50.9% (95% CI (39.5–62.3)) versus 45.6% (95% CI (25.6–65.6)) for path_MSH2 carriers with truncating or missense/aberrant splicing variants, respectively. This evidence concerns the gene MSH2 and endometrial cancer.